<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03935087</url>
  </required_header>
  <id_info>
    <org_study_id>SAVE-ICD</org_study_id>
    <nct_id>NCT03935087</nct_id>
  </id_info>
  <brief_title>Improvement of Left Ventricular Ejection Fraction in ICD Patients Undergoing Therapy With Sacubitril/Valsartan</brief_title>
  <acronym>SAVE-ICD</acronym>
  <official_title>Improvement of Left Ventricular Ejection Fraction in ICD Patients Undergoing Therapy With Sacubitril/Valsartan and Potential Impact on ICD Implant Rates for Primary Prevention of Sudden Cardiac Death (SAVE-ICD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Cardinale G. Panico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Cardinale G. Panico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to evaluate the improvement of the left ventricular volumes and of the
      left ventricular ejection fraction in a population of ICD patients with heart failure and
      left ventricle systolic dysfunction undergoing therapy with Sacubitril/Valsartan (according
      to current Guidelines), during a 6-month follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consecutive, unselected patients with heart failure and left ventricle systolic dysfunction,
      carrying a single-chamber or a bicameral implantable cardioverter defibrillator (ICD) for
      primary prevention of sudden death, undergoing therapy with Sacubitril/Valsartan (according
      to current Guidelines) will be enrolled in the study. A two-dimensional echocardiogram with
      evaluation of left ventricular end-diastolic volume, left ventricular end-systolic volume,
      and left ventricular ejection fraction will be performed, according to standard clinical
      practice, at the beginning of the observation, and at a 6-month follow-up. The improvement of
      the left ventricle volumes and of the left ventricular ejection fraction will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Improvement in left ventricular ejection fraction</measure>
    <time_frame>at enrollment and at 6 months of follow-up</time_frame>
    <description>Difference between the ejection fraction observed at baseline and that observed at 6 months of follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in left ventricle volumes</measure>
    <time_frame>at enrollment and at 6 months of follow-up</time_frame>
    <description>Difference between the left ventricle volumes measured at baseline and those measured at 6 months of follow-up</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>two-dimensional echocardiogram</intervention_name>
    <description>two-dimensional echocardiogram with evaluation of left ventricle volumes and of left ventricular ejection fraction</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with heart failure, left ventricular systolic dysfunction, carrying a
        single-chamber or a bicameral implantable cardioverter defibrillator implanted for primary
        prevention of sudden death, and undergoing therapy with Sacubitril/Valsartan according to
        current Guidelines
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  heart failure

          -  left ventricular systolic dysfunction

          -  carrying a single-chamber or a bicameral implantable cardioverter defibrillator
             implanted for primary prevention of sudden death

          -  undergoing therapy with Sacubitril/Valsartan according to current Guidelines

        Exclusion Criteria:

          -  age &lt;18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>&quot;Card. G. Panico&quot; Hospital</name>
      <address>
        <city>Tricase</city>
        <state>Lecce</state>
        <zip>73039</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pietro Palmisano, MD</last_name>
      <phone>+390833773111</phone>
      <email>dr.palmisano@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Federico Guerra</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Guerra, MD</last_name>
      <phone>+393333862467</phone>
      <email>matziacc@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matteo Ziacchi, MD</last_name>
      <phone>+393476785656</phone>
      <email>matteo.ziacchi@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AO Pugliese-Ciaccio</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vittorio Aspromonte, MD</last_name>
      <phone>+393472536524</phone>
      <email>dott.vittorioaspromonte@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monaldi Hospital</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernesto Ammendola, MD</last_name>
      <phone>+393382841171</phone>
      <email>ammendolaernesto@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU &quot;Maggiore della Carit√†&quot;</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Dell'Era, MD</last_name>
      <phone>+393296575400</phone>
      <email>gdellera@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 30, 2019</study_first_submitted>
  <study_first_submitted_qc>April 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2019</study_first_posted>
  <last_update_submitted>April 30, 2019</last_update_submitted>
  <last_update_submitted_qc>April 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

